Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a-论文-万方医学网

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a

导出原文传递

翻译打印收藏纠错

作者： Marco Battaglini ^[1] ; Hugo Vrenken ^[2] ; Riccardo Tappa Brocci ^[3] ; Giordano Gentile ^[4] ; Ludovico Luchetti ^[5] ; Adriaan Versteeg ^[6] ; Mark S. Freedman ^[7] ; Bernard M. J. Uitdehaag ^[8] ; Ludwig Kappos ^[9] ; Giancarlo Comi ; Andrea Seitzinger ; Dominic Jack ; Maria Pia Sormani ; Frederik Barkhof ; Nicola Stefano

作者单位： Department of Medicine, Surgery and Neurosciences,University of Siena ^[1] Department of Radiology and Nuclear Medicine,Amsterdam UMC ^[2] Department of Medicine,University of Ottawa ^[3] Department of Neurology,Amsterdam UMC, Location VUmc ^[4] Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Neurology ^[5] Casa di Cura Privata del Policlinico,Università Vita‐Salute San Raffaele ^[6] Global Biostatistics,Merck Healthcare KGaA ^[7] Global Medical Affairs,Merck Serono Ltd (an affiliate of Merck KGaA) ^[8] Department of Health Sciences,University of Genoa ^[9]

关键词 first clinical demyelinating event interferon‐beta lesions white matter tracts

发布时间 2022-09-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除